Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expansion

Eli Lilly on Wednesday released new data from the Phase II SYNERGY-NASH trial, demonstrating that its top-selling GLP-1/GIP dual receptor agonist can significantly improve liver fibrosis in patients with nonalcoholic steatohepatitis.